Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

CTI Biopharma | Cell Therapeutics

Request full access

CTI BioPharma | Seeking to Bring New Options to Patients with Blood Cancers

Seattle, United StatesFounded 1992Biotech & Life Sciences

About CTI Biopharma | Cell Therapeutics

CTI BioPharma Corp. is a biopharmaceutical entity that has been acquired by Sobi, a Swedish Orphan Biovitrum AB, in a transaction valued at approximately $1.7 billion, which was completed in June 2023. Prior to this acquisition, the company, originally founded as Cell Therapeutics, Inc. in 1991 by James A. Bianco, was dedicated to the development and commercialization of targeted therapies for blood-related cancers. The company's primary asset is VONJO® (pacritinib), an oral kinase inhibitor.

VONJO is specifically approved for the treatment of adult patients with intermediate or high-risk primary or secondary myelofibrosis, a rare type of bone marrow cancer, who have a low platelet count (thrombocytopenia). The U.S. Food and Drug Administration (FDA) granted this treatment an accelerated approval in February 2022, a significant milestone for the company as it addressed an unmet medical need for this patient population. The drug functions by inhibiting JAK2, IRAK1, and CSF1R, which are involved in the signaling pathways that contribute to myelofibrosis.

The company's business model revolved around the research, development, and subsequent commercialization of its pharmaceutical products. Revenue was primarily generated from the sales of its approved drug, VONJO. The acquisition by Sobi was a strategic move to leverage Sobi's global presence and resources to enhance the commercialization and reach of pacritinib. The deal was structured as an all-cash tender offer for all outstanding shares of CTI BioPharma.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 1997
Outcome tier
Unicorn$1–10B valuation tier

CTI Biopharma | Cell Therapeutics in the Seattle ecosystem

Live from Dealroom

The CTI Biopharma | Cell Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later3 investors entered at this stage

  • Inc.
  • Hercules Capital
  • NEA
Team profiled 21 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 5 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
4 countries with
team presence
🇺🇸 United States87.9%
🇮🇹 Italy6.1%
🇻🇳 Vietnam3%
🇨🇳 China3%
4 countries shown
Web traffic by country
730 monthly visits
across markets
🏳️ Russian Federation95.9%
Top 1 markets shown

Patents

Estimated portfolio value
$12M

7 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about CTI Biopharma | Cell Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See CTI Biopharma | Cell Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.